Targeting matrix metalloproteinases: Exploring the dynamics of the S1′ pocket in the design of selective, small molecule inhibitors

Journal of Medicinal Chemistry

Volumn 57, Issue 24, 2014, Pages 10205-10219

  Fabre, Benjamin ^a,b   Ramos, Ana ^a   De Pascual Teresa, Beatriz ^a  

^a UNIVERSIDAD SAN PABLO CEU   (Spain)

^b INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE 3; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 20; MATRIX METALLOPROTEINASE INHIBITOR; NEUTROPHIL COLLAGENASE; STROMELYSIN;

ARTHRITIS; ARTICLE; CATALYSIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG BINDING; DRUG DESIGN; DRUG STRUCTURE; DRUG TARGETING; DYNAMICS; ENZYME ACTIVE SITE; EXPERIMENTAL STUDY; CHEMISTRY; DRUG EFFECTS; HUMAN; PROTEIN CONFORMATION;

DRUG DESIGN; HUMANS; MATRIX METALLOPROTEINASE INHIBITORS; MATRIX METALLOPROTEINASES; PROTEIN CONFORMATION;

EID: 84920180806     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500505f     Document Type: Article

References (115)

1. Brinckerhoff, C. E.; Matrisian, L. M. Matrix metalloproteinases: a tail of a frog that became a prince Nat. Rev. Mol. Cell Biol. 2002, 3, 207-214
2. Coussens, L. M.; Fingleton, B.; Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer-trials and tribulations Science 2002, 295, 2387-2392
3. Overall, C. M.; Kleifeld, O. Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy Nat. Rev. Cancer 2006, 6, 227-239
4. Renkiewicz, R.; Qiu, L.; Lesch, C.; Sun, X.; Devalaraja, R.; Cody, T.; Kaldjian, E.; Welgus, H.; Baragi, V. Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats Arthritis Rheum. 2003, 48, 1742-1749
5. Holmbeck, K.; Bianco, P.; Caterina, J.; Yamada, S.; Kromer, M.; Kuznetsov, S. A.; Mankani, M.; Gehron Robey, P.; Poole, A. R.; Pidoux, I. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover Cell 1999, 99, 81-92
6. Maskos, K. Crystal structures of MMPs in complex with physiological and pharmacological inhibitors Biochimie 2005, 87, 249-263
7. Devel, L.; Czarny, B.; Beau, F.; Georgiadis, D.; Stura, E.; Dive, V. Third generation of matrix metalloprotease inhibitors: gain in selectivity by targeting the depth of the S1′ cavity Biochimie 2010, 92, 1501-1508
8. Beckett, R. P.; Davidson, A. H.; Drummond, A. H.; Huxley, P.; Whittaker, M. Recent advances in matrix metalloproteinase inhibitor research Drug Discovery Today 1996, 1, 16-26
9. Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J. H. Design and therapeutic application of matrix metalloproteinase inhibitors Chem. Rev. 1999, 99, 2735-2776
10. Fisher, J. F.; Mobashery, S. Recent advances in MMP inhibitor design Cancer Metastasis Rev. 2006, 25, 115-136
11. Terp, G. E.; Cruciani, G.; Christensen, I. T.; Jørgensen, F. S. Structural differences of matrix metalloproteinases with potential implications for inhibitor selectivity examined by the GRID/CPCA approach J. Med. Chem. 2002, 45, 2675-2684
12. Pirard, B. Insight into the structural determinants for selective inhibition of matrix metalloproteinases Drug Discovery Today 2007, 12, 640-646
13. Pirard, B.; Matter, H. Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis J. Med. Chem. 2006, 49, 51-69
14. Serra, P.; Bruczko, M.; Zapico, J.; Puckowska, A.; García, M.; Martín-Santamaría, S.; Ramos, A.; de Pascual-Teresa, B. MMP-2 selectivity in hydroxamate-type inhibitors Curr. Med. Chem. 2012, 19, 1036-1064
15. Lukacova, V.; Zhang, Y.; Mackov, M.; Baricic, P.; Raha, S.; Calvo, J. A.; Balaz, S. Similarity of binding sites of human matrix metalloproteinases J. Biol. Chem. 2004, 279, 14194-14200
16. Moy, F. J.; Chanda, P. K.; Chen, J.; Cosmi, S.; Edris, W.; Levin, J. I.; Rush, T. S.; Wilhelm, J.; Powers, R. Impact of mobility on structure-based drug design for the MMPs J. Am. Chem. Soc. 2002, 124, 12658-12659
17. Bertini, I.; Fragai, M.; Luchinat, C. Intra- and interdomain flexibility in matrix metalloproteinases: functional aspects and drug design Curr. Pharm. Des. 2009, 15, 3592-3605
18. Bode, W.; Gomis-Rüth, F. X.; Stockler, W. Astacins, serralysins, snake venom and matrix metalloproteinases exhibit identical zinc-binding environments (HEXXHXXGXXH and Met-turn) and topologies and should be grouped into a common family, the "metzincins" FEBS Lett. 1993, 331, 134-40
19. Visse, R.; Nagase, H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases Circ. Res. 2003, 92, 827-839
20. Wetmore, D. R.; Hardman, K. D. Roles of the propeptide and metal ions in the folding and stability of the catalytic domain of stromelysin (matrix metalloproteinase 3) Biochemistry 1996, 35, 6549-6558
21. Hashimoto, H.; Takeuchi, T.; Komatsu, K.; Miyazaki, K.; Sato, M.; Higashi, S. Structural basis for matrix metalloproteinase-2 (MMP-2)-selective inhibitory action of β-amyloid precursor protein-derived inhibitor J. Biol. Chem. 2011, 286, 33236-33243
22. Schechter, I.; Berger, A. On the size of the active site in proteases. I. Papain Biochem. Biophys. Res. Commun. 1967, 27, 157-162
23. Arendt, Y.; Banci, L.; Bertini, I.; Cantini, F.; Cozzi, R.; Del Conte, R.; Gonnelli, L. Catalytic domain of MMP20 (enamelysin)-the NMR structure of a new matrix metalloproteinase FEBS Lett. 2007, 581, 4723-4726
24. Bertini, I.; Fragai, M.; Luchinat, C.; Melikian, M.; Toccafondi, M.; Lauer, J. L.; Fields, G. B. Structural basis for matrix metalloproteinase 1-catalyzed collagenolysis J. Am. Chem. Soc. 2012, 134, 2100-2110
25. Boehr, D. D.; Nussinov, R.; Wright, P. E. The role of dynamic conformational ensembles in biomolecular recognition Nat. Chem. Biol. 2009, 5, 789-796
26. Schindler, T.; Bornmann, W.; Pellicena, P.; Miller, W. T.; Clarkson, B.; Kuriyan, J. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase Science 2000, 289, 1938-1942
27. Huse, M.; Kuriyan, J. The conformational plasticity of protein kinases Cell 2002, 109, 275-282
28. Capdeville, R.; Buchdunger, E.; Zimmermann, J.; Matter, A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug Nat. Rev. Drug Discovery 2002, 1, 493-502
29. Jarymowycz, V. A.; Stone, M. J. Fast time scale dynamics of protein backbones: NMR relaxation methods, applications, and functional consequences Chem. Rev. 2006, 106, 1624-1671
30. Henzler-Wildman, K.; Kern, D. Dynamic personalities of proteins Nature 2007, 450, 964-972
31. Bertini, I.; Calderone, V.; Cosenza, M.; Fragai, M.; Lee, Y. M.; Luchinat, C.; Mangani, S.; Terni, B.; Turano, P. Conformational variability of matrix metalloproteinases: beyond a single 3D structure Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 5334-5339
32. Bertini, I.; Calderone, V.; Fragai, M.; Jaiswal, R.; Luchinat, C.; Melikian, M.; Mylonas, E.; Svergun, D. I. Evidence of reciprocal reorientation of the catalytic and hemopexin-like domains of full-length MMP-12 J. Am. Chem. Soc. 2008, 130, 7011-7021
33. Frauenfelder, H.; Petsko, G. A.; Tsernoglou, D. Temperature-dependent X-ray diffraction as a probe of protein structural dynamics Nature 1979, 280, 558-563
34. Lipari, G.; Szabo, A. Model-free approach to the interpretation of nuclear magnetic resonance relaxation in macromolecules. 1. Theory and range of validity J. Am. Chem. Soc. 1982, 104, 4546-4559
35. Lipari, G.; Szabo, A. Model-free approach to the interpretation of nuclear magnetic resonance relaxation in macromolecules. 2. Analysis of experimental results J. Am. Chem. Soc. 1982, 104, 4559-4570
36. Clore, G. M.; Szabo, A.; Bax, A.; Kay, L. E.; Driscoll, P. C.; Gronenborn, A. M. Deviations from the simple two-parameter model-free approach to the interpretation of nitrogen-15 nuclear magnetic relaxation of proteins J. Am. Chem. Soc. 1990, 112, 4989-4991
37. Mandel, A. M.; Akke, M.; Palmer, A. G., III. Backbone dynamics of Escherichia coli ribonuclease HI: correlations with structure and function in an active enzyme J. Mol. Biol. 1995, 246, 144-163
38. Csermely, P.; Palotai, R.; Nussinov, R. Induced fit, conformational selection and independent dynamic segments: an extended view of binding events Trends Biochem. Sci. 2010, 35, 539-546
39. Hammes, G. G.; Chang, Y.-C.; Oas, T. G. Conformational selection or induced fit: a flux description of reaction mechanism Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 13737-13741
40. Aleksandrov, A.; Simonson, T. Molecular dynamics simulations show that conformational selection governs the binding preferences of imatinib for several tyrosine kinases J. Biol. Chem. 2010, 285, 13807-13815
41. Cozzini, P.; Kellogg, G. E.; Spyrakis, F.; Abraham, D. J.; Costantino, G.; Emerson, A.; Fanelli, F.; Gohlke, H.; Kuhn, L. A.; Morris, G. M. Target flexibility: an emerging consideration in drug discovery and design J. Med. Chem. 2008, 51, 6237-6255
42. Liu, Y.; Gray, N. S. Rational design of inhibitors that bind to inactive kinase conformations Nat. Chem. Biol. 2006, 2, 358-364
43. Pargellis, C.; Tong, L.; Churchill, L.; Cirillo, P. F.; Gilmore, T.; Graham, A. G.; Grob, P. M.; Hickey, E. R.; Moss, N.; Pav, S. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site Nat. Struct. Mol. Biol. 2002, 9, 268-272
44. Copeland, R. A.; Pompliano, D. L.; Meek, T. D. Drug-target residence time and its implications for lead optimization Nat. Rev. Drug Discovery 2006, 5, 730-739
45. Copeland, R. A. Conformational adaptation in drug-target interactions and residence time Future Med. Chem. 2011, 3, 1491-1501
46. Van Doren, S. R.; Kurochkin, A. V.; Hu, W.; Ye, Q. Z.; Johnson, L. L.; Hupe, D. J.; Zuiderweg, E. R. Solution structure of the catalytic domain of human stromelysin complexed with a hydrophobic inhibitor Protein Sci. 1995, 4, 2487-2498
47. Gooley, P. R.; O'Connell, J. F.; Marcy, A. I.; Cuca, G. C.; Salowe, S. P.; Bush, B. L.; Hermes, J. D.; Esser, C. K.; Hagmann, W. K.; Springer, J. P.; Bruce, A. J. The NMR structure of the inhibited catalytic domain of human stromelysin-1 Nat. Struct. Biol. 1994, 1, 111-118
48. Díaz, N.; Suárez, D. Molecular dynamics simulations of matrix metalloproteinase 2: role of the structural metal ions Biochemistry 2007, 46, 8943-8952
49. Gooley, P. R.; O'Connell, J. F.; Marcy, A. I.; Cuca, G. C.; Axel, M. G.; Caldwell, C. G.; Hagmann, W. K.; Becker, J. W. Comparison of the structure of human recombinant short form stromelysin by multidimensional heteronuclear NMR and X-ray crystallography J. Biomol. NMR 1996, 7, 8-28
50. Pavlovsky, A. G.; Williams, M. G.; Ye, Q. Z.; Ortwine, D. F.; Purchase, C. F.; White, A. D.; Dhanaraj, V.; Roth, B. D.; Johnson, L. L.; Hupe, D.; Humblet, C.; Blundell, T. L. X-ray structure of human stromelysin catalytic domain complexed with nonpeptide inhibitors: implications for inhibitor selectivity Protein Sci. 1999, 8, 1455-1462
51. Becker, J. W.; Marcy, A. I.; Rokosz, L. L.; Axel, M. G.; Burbaum, J. J.; Fitzgerald, P. M.; Cameron, P. M.; Esser, C. K.; Hagmann, W. K.; Hermes, J. D.; Springer, J. P. Stromelysin-1: three-dimensional structure of the inhibited catalytic domain and of the C-truncated proenzyme Protein Sci. 1995, 4, 1966-1976
52. Finzel, B. C.; Baldwin, E. T.; Bryant, G. L., Jr.; Hess, G. F.; Wilks, J. W.; Trepod, C. M.; Mott, J. E.; Marshall, V. P.; Petzold, G. L.; Poorman, R. A.; O'Sullivan, T. J.; Schostarez, H. J.; Mitchell, M. A. Structural characterizations of nonpeptidic thiadiazole inhibitors of matrix metalloproteinases reveal the basis for stromelysin selectivity Protein Sci. 1998, 7, 2118-2126
53. 15N NMR relaxation measurements: comparison of ligand binding to the S1-S3 and S′1-S′3 subsites J. Biomol. NMR 1999, 15, 55-64
54. Chen, L.; Rydel, T. J.; Gu, F.; Dunaway, C. M.; Pikul, S.; Dunham, K. M. D.; Barnett, B. L. Crystal structure of the stromelysin catalytic domain at 2.0 Å resolution: inhibitor-induced conformational changes J. Mol. Biol. 1999, 293, 545-557
55. 3 subsites Biochim. Biophys. Acta 1999, 1434, 304-316
56. Lovejoy, B.; Cleasby, A.; Hassell, A. M.; Longley, K.; Luther, M. A.; Weigl, D.; McGeehan, G.; McElroy, A. B.; Drewry, D.; Lambert, M. H.; Jordan, S. R. Structure of the catalytic domain of fibroblast collagenase complexed with an inhibitor Science 1994, 263, 375-377
57. Lovejoy, B.; Hassell, A. M.; Luther, M. A.; Weigl, D.; Jordan, S. R. Crystal structures of recombinant 19-kDa human fibroblast collagenase complexed to itself Biochemistry 1994, 33, 8207-8217
58. Moy, F. J.; Pisano, M. R.; Chanda, P. K.; Urbano, C.; Killar, L. M.; Sung, M.-L.; Powers, R. Assignments, secondary structure and dynamics of the inhibitor-free catalytic fragment of human fibroblast collagenase J. Biomol. NMR 1997, 10, 9-19
59. Moy, F. J.; Chanda, P. K.; Chen, J. M.; Cosmi, S.; Edris, W.; Skotnicki, J. S.; Wilhelm, J.; Powers, R. NMR solution structure of the catalytic fragment of human fibroblast collagenase complexed with a sulfonamide derivative of a hydroxamic acid compound Biochemistry 1999, 38, 7085-7096
60. Moy, F. J.; Chanda, P. K.; Cosmi, S.; Pisano, M. R.; Urbano, C.; Wilhelm, J.; Powers, R. High-resolution solution structure of the inhibitor-free catalytic fragment of human fibroblast collagenase determined by multidimensional NMR Biochemistry 1998, 37, 1495-1504
61. Lovejoy, B.; Welch, A. R.; Carr, S.; Luong, C.; Broka, C.; Hendricks, R. T.; Campbell, J. A.; Walker, K. A.; Martin, R.; Van Wart, H.; Browner, M. F. Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors Nat. Struct. Biol. 1999, 6, 217-221
62. Borkakoti, N.; Winkler, F. K.; Williams, D. H.; D'Arcy, A.; Broadhurst, M. J.; Brown, P. A.; Johnson, W. H.; Murray, E. J. Structure of the catalytic domain of human fibroblast collagenase complexed with an inhibitor Nat. Struct. Biol. 1994, 1, 106-110
63. Feng, Y.; Likos, J. J.; Zhu, L.; Woodward, H.; Munie, G.; McDonald, J. J.; Stevens, A. M.; Howard, C. P.; De Crescenzo, G. A.; Welsch, D. Solution structure and backbone dynamics of the catalytic domain of matrix metalloproteinase-2 complexed with a hydroxamic acid inhibitor Biochim. Biophys. Acta 2002, 1598, 10-23
64. Morgunova, E.; Tuuttila, A.; Bergmann, U.; Isupov, M.; Lindqvist, Y.; Schneider, G.; Tryggvason, K. Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed Science 1999, 284, 1667-1670
65. Dhanaraj, V.; Williams, M. G.; Ye, Q.-Z.; Molina, F.; Johnson, L. L.; Ortwine, D. F.; Pavlovsky, A.; Rubin, J. R.; Skeean, R. W.; White, A. D. X-ray structure of gelatinase A catalytic domain complexed with a hydroxamate inhibitor Croat. Chem. Acta 1999, 72, 575-591
66. Edman, K.; Furber, M.; Hemsley, P.; Johansson, C.; Pairaudeau, G.; Petersen, J.; Stocks, M.; Tervo, A.; Ward, A.; Wells, E. The discovery of MMP7 inhibitors exploiting a novel selectivity trigger ChemMedChem 2011, 6, 769-773
67. Betz, M.; Huxley, P.; Davies, S. J.; Mushtaq, Y.; Pieper, M.; Tschesche, H.; Bode, W.; Gomis-Ruth, F. X. 1.8-Å crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate primed-side inhibitor with a distinct selectivity profile Eur. J. Biochem. 1997, 247, 356-363
68. Bertini, I.; Calderone, V.; Fragai, M.; Luchinat, C.; Maletta, M.; Yeo, K. J. Snapshots of the reaction mechanism of matrix metalloproteinases Angew. Chem., Int. Ed. 2006, 45, 7952-7955
69. Pochetti, G.; Gavuzzo, E.; Campestre, C.; Agamennone, M.; Tortorella, P.; Consalvi, V.; Gallina, C.; Hiller, O.; Tschesche, H.; Tucker, P. A. Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates J. Med. Chem. 2006, 49, 923-931
70. Gavuzzo, E.; Pochetti, G.; Mazza, F.; Gallina, C.; Gorini, B.; D'Alessio, S.; Pieper, M.; Tschesche, H.; Tucker, P. A. Two crystal structures of human neutrophil collagenase, one complexed with a primed- and the other with an unprimed-side inhibitor: implications for drug design J. Med. Chem. 2000, 43, 3377-3385
71. Brandstetter, H.; Grams, F.; Glitz, D.; Lang, A.; Huber, R.; Bode, W.; Krell, H. W.; Engh, R. A. The 1.8-Å crystal structure of a matrix metalloproteinase 8-barbiturate inhibitor complex reveals a previously unobserved mechanism for collagenase substrate recognition J. Biol. Chem. 2001, 276, 17405-17412
72. Grams, F.; Reinemer, P.; Powers, J. C.; Kleine, T.; Pieper, M.; Tschesche, H.; Huber, R.; Bode, W. X-ray structures of human neutrophil collagenase complexed with peptide hydroxamate and peptide thiol inhibitors. Implications for substrate binding and rational drug design Eur. J. Biochem. 1995, 228, 830-841
73. Rowsell, S.; Hawtin, P.; Minshull, C. A.; Jepson, H.; Brockbank, S.; Barratt, D. G.; Slater, A. M.; McPheat, W. L.; Waterson, D.; Henney, A. M. Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor J. Mol. Biol. 2002, 319, 173-181
74. Tochowicz, A.; Maskos, K.; Huber, R.; Oltenfreiter, R.; Dive, V.; Yiotakis, A.; Zanda, M.; Bode, W.; Goettig, P. Crystal structures of MMP-9 complexes with five inhibitors: contribution of the flexible Arg424 side-chain to selectivity J. Mol. Biol. 2007, 371, 989-1006
75. Lang, R.; Kocourek, A.; Braun, M.; Tschesche, H.; Huber, R.; Bode, W.; Maskos, K. Substrate specificity determinants of human macrophage elastase (MMP-12) based on the 1.1 Å crystal structure J. Mol. Biol. 2001, 312, 731-742
76. Moy, F. J.; Chanda, P. K.; Chen, J. M.; Cosmi, S.; Edris, W.; Levin, J. I.; Powers, R. High-resolution solution structure of the catalytic fragment of human collagenase-3 (MMP-13) complexed with a hydroxamic acid inhibitor J. Mol. Biol. 2000, 302, 671-689
77. Zhang, X.; Gonnella, N. C.; Koehn, J.; Pathak, N.; Ganu, V.; Melton, R.; Parker, D.; Hu, S. I.; Nam, K. Y. Solution structure of the catalytic domain of human collagenase-3 (MMP-13) complexed to a potent non-peptidic sulfonamide inhibitor: binding comparison with stromelysin-1 and collagenase-11 J. Mol. Biol. 2000, 301, 513-524
78. Alcaraz, L. A.; Banci, L.; Bertini, I.; Cantini, F.; Donaire, A.; Gonnelli, L. Matrix metalloproteinase-inhibitor interaction: the solution structure of the catalytic domain of human matrix metalloproteinase-3 with different inhibitors J. Biol. Inorg. Chem. 2007, 12, 1197-1206
79. Zucker, S.; Jian, C. A. O.; Chen, W. T. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment Oncogene 2000, 19, 6642-6650
80. Pavlaki, M.; Zucker, S. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials Cancer Metastasis Rev. 2003, 22, 177-203
81. Zapico, J. M.; Serra, P.; Garcia-Sanmartin, J.; Filipiak, K.; Carbajo, R. J.; Schott, A. K.; Pineda-Lucena, A.; Martinez, A.; Martin-Santamaria, S.; Ramos, A.; de Pascual-Teresa, B. Potent "clicked" MMP2 inhibitors: synthesis, molecular modeling and biological exploration Org. Biomol. Chem. 2011, 9, 4587-4599
82. Fabre, B.; Filipiak, K.; Zapico, J. M.; Díaz, N.; Carbajo, R. J.; Schott, A. K.; Martínez-Alcázar, M. P.; Suárez, D.; Pineda-Lucena, A.; Ramos, A.; de Pascual-Teresa, B. Progress towards water-soluble triazole-based selective MMP-2 inhibitors Org. Biomol. Chem. 2013, 11, 6623-6641
83. Fabre, B.; Filipiak, K.; Díaz, N.; Zapico, J. M.; Suárez, D.; Ramos, A.; de Pascual-Teresa, B. An integrated computational and experimental approach to gain selectivity for MMP-2 within the gelatinases subfamily ChemBioChem 2014, 15, 399-412
84. Cheng, X.-C.; Wang, Q.; Fang, H.; Xu, W.-F. Role of sulfonamide group in matrix metalloproteinase inhibitors Curr. Med. Chem. 2008, 15, 368-373
85. Pochetti, G.; Montanari, R.; Gege, C.; Chevrier, C.; Taveras, A. G.; Mazza, F. Extra binding region induced by non-zinc chelating inhibitors into the S(1)′ subsite of matrix metalloproteinase 8 (MMP-8) J. Med. Chem. 2009, 52, 1040-1049
86. Morales, R.; Perrier, S.; Florent, J. M.; Beltra, J.; Dufour, S.; De Mendez, I.; Manceau, P.; Tertre, A.; Moreau, F.; Compere, D. Crystal structures of novel non-peptidic, non-zinc chelating inhibitors bound to MMP-12 J. Mol. Biol. 2004, 341, 1063-1076
87. Devel, L.; Garcia, S.; Czarny, B.; Beau, F.; Lajeunesse, E.; Vera, L.; Georgiadis, D.; Stura, E.; Dive, V. Insights from selective non-phosphinic inhibitors of MMP-12 tailored to fit with an S1′ loop canonical conformation J. Biol. Chem. 2010, 285, 35900-35909
88. Devel, L.; Beau, F.; Amoura, M.; Vera, L.; Cassar-Lajeunesse, E.; Garcia, S.; Czarny, B.; Stura, E. A.; Dive, V. Simple pseudo-dipeptides with a P2′ glutamate a novel inhibitor family of matrix metalloproteases and other metzincins J. Biol. Chem. 2012, 287, 26647-26656
89. Chen, J. M.; Nelson, F. C.; Levin, J. I.; Mobilio, D.; Moy, F. J.; Nilakantan, R.; Zask, A.; Powers, R. Structure-based design of a novel, potent, and selective inhibitor for MMP-13 utilizing NMR spectroscopy and computer-aided molecular design J. Am. Chem. Soc. 2000, 122, 9648-9654
90. Engel, C. K.; Pirard, B.; Schimanski, S.; Kirsch, R.; Habermann, J.; Klingler, O.; Schlotte, V.; Weithmann, K. U.; Wendt, K. U. Structural basis for the highly selective inhibition of MMP-13 Chem. Biol. 2005, 12, 181-189
91. Johnson, A. R.; Pavlovsky, A. G.; Ortwine, D. F.; Prior, F.; Man, C. F.; Bornemeier, D. A.; Banotai, C. A.; Mueller, W. T.; McConnell, P.; Yan, C. Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects J. Biol. Chem. 2007, 282, 27781-27791
92. Li, J. J.; Nahra, J.; Johnson, A. R.; Bunker, A.; O'Brien, P.; Yue, W.-S.; Ortwine, D. F.; Man, C.-F.; Baragi, V.; Kilgore, K. Quinazolinones and pyrido[3,4- d ]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis J. Med. Chem. 2008, 51, 835-841
93. Heim-Riether, A.; Taylor, S. J.; Liang, S.; Gao, D. A.; Xiong, Z.; Michael August, E.; Collins, B. K.; Farmer, B. T., II; Haverty, K.; Hill-Drzewi, M. Improving potency and selectivity of a new class of non-Zn-chelating MMP-13 inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 5321-5324
94. Gao, D. A.; Xiong, Z.; Heim-Riether, A.; Amodeo, L.; August, E. M.; Cao, X.; Ciccarelli, L.; Collins, B. K.; Harrington, K.; Haverty, K. SAR studies of non-zinc-chelating MMP-13 inhibitors: improving selectivity and metabolic stability Bioorg. Med. Chem. Lett. 2010, 20, 5039-5043
95. Schnute, M. E.; O'Brien, P. M.; Nahra, J.; Morris, M.; Howard Roark, W.; Hanau, C. E.; Ruminski, P. G.; Scholten, J. A.; Fletcher, T. R.; Hamper, B. C. Discovery of (pyridin-4-yl)-2 H -tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis Bioorg. Med. Chem. Lett. 2010, 20, 576-580
96. Taylor, S. J.; Abeywardane, A.; Liang, S.; Muegge, I.; Padyana, A.; Xiong, Z.; Hill-Drzewi, M.; Farmer, B.; Li, X.; Collins, B. Fragment based discovery of indole inhibitors of matrix metalloproteinase-13 J. Med. Chem. 2011, 54, 8174-8187
97. Savi, C. D.; Morley, A. D.; Ting, A.; Nash, I.; Karabelas, K.; Wood, C. M.; James, M.; Norris, S. J.; Karoutchi, G.; Rankine, N. Selective non zinc binding inhibitors of MMP13 Bioorg. Med. Chem. Lett. 2011, 21, 4215-4219
98. De Savi, C.; Morley, A. D.; Nash, I.; Karoutchi, G.; Page, K.; Ting, A.; Gerhardt, S. Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2 Bioorg. Med. Chem. Lett. 2012, 22, 271-277
99. Gege, C.; Bao, B.; Bluhm, H.; Boer, J. r.; Gallagher, B. M., Jr.; Korniski, B.; Powers, T. S.; Steeneck, C.; Taveras, A. G.; Baragi, V. M. Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis J. Med. Chem. 2012, 55, 709-716
100. Stura, E. A.; Visse, R.; Cuniasse, P.; Dive, V.; Nagase, H. Crystal structure of full-length human collagenase 3 (MMP-13) with peptides in the active site defines exosites in the catalytic domain FASEB J. 2013, 27, 4395-4405
101. Fingleton, B. Matrix metalloproteinases as valid clinical target Curr. Pharm. Des 2007, 13, 333-346
102. Díaz, N.; Suárez, D.; Valdés, H. From the X-ray compact structure to the elongated form of the full-length MMP-2 enzyme in solution: a molecular dynamics study J. Am. Chem. Soc. 2008, 130, 14070-14071
103. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking J. Mol. Biol. 1997, 267, 727-748
104. Rarey, M.; Kramer, B.; Lengauer, T.; Klebe, G. A fast flexible docking method using an incremental construction algorithm J. Mol. Biol. 1996, 261, 470-489
105. Totrov, M.; Abagyan, R. Flexible ligand docking to multiple receptor conformations: a practical alternative Curr. Opin. Struct. Biol. 2008, 18, 178-184
106. Kallblad, P.; Todorov, N. P.; Willems, H. M.; Alberts, I. L. Receptor flexibility in the in silico screening of reagents in the S1′ pocket of human collagenase J. Med. Chem. 2004, 47, 2761-2767
107. Alberts, I. L.; Todorov, N. P.; Dean, P. M. Receptor flexibility in de novo ligand design and docking J. Med. Chem. 2005, 48, 6585-6596
108. Lill, M. A. Efficient incorporation of protein flexibility and dynamics into molecular docking simulations Biochemistry 2011, 50, 6157-6169
109. Lin, J.-H. Accommodating protein flexibility for structure-based drug design Curr. Top. Med. Chem. 2011, 11, 171-178
110. Czarny, B.; Stura, E. A.; Devel, L.; Vera, L.; Cassar-Lajeunesse, E.; Beau, F.; Calderone, V.; Fragai, M.; Luchinat, C.; Dive, V. Molecular determinants of a selective matrix metalloprotease-12 inhibitor: insights from crystallography and thermodynamic studies J. Med. Chem. 2013, 56, 1149-1159
111. Brown, S.; Bernardo, M. M.; Li, Z. H.; Kotra, L. P.; Tanaka, Y.; Fridman, R.; Mobashery, S. Potent and selective mechanism-based inhibition of gelatinases J. Am. Chem. Soc. 2000, 122, 6799-6800
112. Forbes, C.; Shi, Q.; Fisher, J. F.; Lee, M.; Hesek, D.; Llarrull, L. I.; Toth, M.; Gossing, M.; Fridman, R.; Mobashery, S. Active site ring-opening of a thiirane moiety and picomolar inhibition of gelatinases Chem. Biol. Drug Des. 2009, 74, 527-534
113. Tao, P.; Fisher, J. F.; Shi, Q.; Vreven, T.; Mobashery, S.; Schlegel, H. B. Matrix metalloproteinase 2 (MMP2) inhibition: QM/MM studies of the inhibition mechanism of SB-3CT and its analog Biochemistry 2009, 48, 9839-9847
114. Fabre, B.; Filipiak, K.; Coderch, C.; Zapico, J.; Carbajo, R. J.; Schott, A. K.; Pineda-Lucena, A.; de Pascual-Teresa, B.; Ramos, A. New clicked thiirane derivatives as gelatinase inhibitors: the relevance of the P1′ segment RSC Adv. 2014, 4, 17726-17735
115. Tao, P.; Fisher, J. F.; Mobashery, S.; Schlegel, H. B. DFT studies of the ring-opening mechanism of SB-3CT, a potent inhibitor of matrix metalloproteinase 2 Org. Lett. 2009, 11, 2559-2562